Outlook Therapeutics Inc.
(OTLK)
undefined
undefined%
At close: undefined
2.27
1.45%
After-hours Jan 03, 2025, 05:07 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
| Revenue | n/a | n/a | n/a | n/a | n/a | 8.15M | 3.09M | 3.81M | 2.98M | 5.22M | 9.05M |
| Cost of Revenue | n/a | 44.19K | 204.69K | 262.14K | 554.07K | 23.80K | 18.50K | 23.81K | 32.76K | 38.88K | 14.12K |
| Gross Profit | n/a | -44.19K | -204.69K | -262.14K | -554.07K | 8.12M | 3.07M | 3.79M | 2.95M | 5.18M | 9.04M |
| Operating Income | -71,703.20B | -53.13M | -63.07M | -51.73M | -36.84M | -36.30M | -25.44M | -35.88M | -51.76M | -46.56M | -12.39M |
| Interest Income | -906.15B | 1.56K | 1.49K | 936.13 | 1.76K | 3.47K | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -75,363.90B | -58.98M | -66.05M | -53.16M | -38.51M | -37.93M | -33.74M | -38.35M | -53.23M | -48.86M | -13.29M |
| Net Income | -75,366.70B | -58.98M | -66.05M | -53.16M | -35.24M | -34.52M | -46.11M | -38.85M | -53.33M | -47.39M | -13.73M |
| Selling & General & Admin | 29,940.20B | 26.67M | 20.74M | 13.05M | 8.08M | 5.52M | 6.97M | 13.19M | 19.17M | 12.91M | 7.32M |
| Research & Development | 41,763.00B | 26.45M | 42.33M | 38.96M | 26.34M | 23.81M | 18.50M | 23.81M | 32.76M | 38.88M | 14.12M |
| Other Expenses | n/a | n/a | -882.90K | n/a | n/a | n/a | n/a | n/a | 0.00 | n/a | n/a |
| Operating Expenses | 71,703.20B | 53.13M | 63.07M | 51.73M | 36.31M | 29.33M | 25.48M | 39.69M | 51.93M | 51.78M | 21.44M |
| Interest Expense | 3,157.00B | 1.56M | 1.49M | 936.00K | 1.76M | 3.47M | 3.89M | 5.63M | 1.47M | 2.30M | 901.05K |
| Selling & Marketing Expenses | n/a | n/a | n/a | 279.68K | -1.90M | -3.85M | -7.25M | -2.69M | -2.47M | n/a | n/a |
| Cost & Expenses | n/a | 53.13M | 63.07M | 51.73M | 36.31M | 32.69M | 28.53M | 39.69M | 54.74M | 51.78M | 21.44M |
| Income Tax | 2.80B | 2.80K | 2.80K | 2.00K | -3.27M | -3.41M | -3.65M | 501.50K | 103.00K | -190.11K | 439.02K |
| Shares Outstanding (Basic) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.14K | 107.58K | 93.95K | 88.40K |
| Shares Outstanding (Diluted) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.26K | 107.58K | 93.95K | 88.40K |
| EPS (Basic) | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.7 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS (Diluted) | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.7 | -258.54 | -495.71 | -504.47 | -155.35 |
| EBITDA | -71,703.20B | -57.38M | -62.87M | -51.46M | -35.76M | -31.11M | -26.79M | -30.03M | -48.95M | -44.74M | -11.51M |
| Depreciation & Amortization | n/a | 44.19K | 204.69K | 262.14K | 554.07K | 3.36M | 3.05M | 2.69M | 2.39M | 1.82M | 878.48K |